A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis

Shabaninejad, Hosein; Asgharzadeh, Asra; Rezaei, Nima; Rezapoor, Aziz

doi:10.1586/1744666x.2016.1155452

Cited by 38 publications

(36 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20,29,31,34,35,41,42,56,59,68,72,98-104 This route has also been shown effective and safe in children, 31,37,105-109 elderly (even those on anticoagulation and antiplatelet therapy), 30,69,110 pregnant women 69,111 and obese patients, 112,113 at the same dose recommended for intravenous use.…”

Section: Indications and Efficacy Of Human Immunoglobulin In Primary mentioning

confidence: 99%

See 1 more Smart Citation

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Goudouris

Silva

Ouricuri

et al. 2017

Einstein (São Paulo)

View full text Add to dashboard Cite

In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.

show abstract

Section: Indications and Efficacy Of Human Immunoglobulin In Primary mentioning

confidence: 99%

“…21-27 It has been increasingly used in the last 10 to 15 years, with good clinical results, few adverse effects and other advantages when compared to intravenous, as described later. 28-42 Products for subcutaneous use have been available in Brazil since 2015.…”

Section: Introductionmentioning

confidence: 99%

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Goudouris

Silva

Ouricuri

et al. 2017

Einstein (São Paulo)

View full text Add to dashboard Cite

show abstract

“…effective in preventing infections, it is also associated with headache, fever, allergic reactions and other systemic reactions [13]. In addition, IVIG replacement therapy takes a toll on patients' quality of life because it requires repeated venous access and time-consuming administration in physician offices, outpatient infusion centers or scheduling with a home infusion nurse.…”

mentioning

confidence: 99%

“…As expected, some patients treated with SCIG experience some local pain, itching, erythema, edema and induration at the injection site; however, these reactions are usually mild, resolve within 24-48 h, and decrease in frequency and severity as the therapy continues. However, limitations in the volume that can be infused into subcutaneous tissue with conventional SCIG requires frequent administration (i.e., weekly or biweekly) and multiple infusion sites [7,13].…”

mentioning

confidence: 99%

Recombinant Human Hyaluronidase-Facilitated Subcutaneous Immunoglobulin Infusion in Primary Immunodeficiency Diseases

Wasserman

2017

Immunotherapy

View full text Add to dashboard Cite

Most primary immunodeficiency diseases (PIDDs) resulting in antibody deficiency require intravenous or subcutaneous immunoglobulin G (SCIG) replacement therapy. The flow and distribution of SCIG to the vasculature is impeded by the glycosaminoglycan hyaluronan in the extracellular matrix, which limits the infusion rate and volume per site, necessitating frequent infusions and multiple infusion sites. Hyaluronidase depolymerizes hyaluronan and is a spreading factor for injectable biologics. Recombinant human hyaluronidase (rHuPH20) increases SCIG absorption and dispersion. In patients with PIDD, SCIG facilitated with rHuPH20 (IGHy) has been shown to prevent infections, be well-tolerated and reduce infusion frequency and number of infusion sites as compared with conventional SCIG. This article reviews IGHy clinical studies and real-world practice data in patients with PIDD.

show abstract

“…This is supported by various studies in different countries, all of which suggest that SCIg is less costly than IVIg and that SCIg is a more cost-effective treatment (20). Switching from IVIg to SCIg can significantly reduce the direct costs for patients.…”

Section: Resultsmentioning

confidence: 75%

Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Immunoglobulin (Ig) replacement therapy is used for treating a variety of primary immunodeficiency diseases (PIDs). Ig replacement therapy is the most important therapy for these diseases, since it protects the body against infections and reduces autoimmune disease symptoms. The purpose of this research was to estimate the cost of subcutaneous and intravenous Ig therapy in Iran. Methods: This study is carried out from the perspective of Iran's healthcare system and all the medical costs are calculated. Cost variables include personnel, equipment, and supplies. The data required for cost estimation are obtained from the records of children's Medical center of Tehran for 2015. Personnel and medical treatment costs are calculated based on relative value units. For SCIg, cost items are extracted from the literature. Results: The total cost of IVIg and SCIg for the health system in the first year of treatment is $1370 and $121 respectively. The results indicate that SCIg reduces costs and is the preferred treatment for PID patients. Conclusions: SCIg therapy significantly reduces the costs of the healthcare system compared to IVIg therapy, and this is enough economic justification for introduction of this treatment in the Iranian healthcare system. SCIg is also critical in reducing the direct costs of patients.

show abstract

A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis

Cited by 38 publications

References 43 publications

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Recombinant Human Hyaluronidase-Facilitated Subcutaneous Immunoglobulin Infusion in Primary Immunodeficiency Diseases

Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients

Contact Info

Product

Resources

About